Access the full text.
Sign up today, get DeepDyve free for 14 days.
A Lamarca, DH Palmer, HS Wasan, PJ Ross, YT Ma, A Arora (2021)Advanced Biliary Cancer Working Group. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
Lancet Oncol, 22
Bingqi Ma, H. Meng, Ye Tian, Yingying Wang, T. Song, Ti Zhang, Qiang Wu, Yunlong Cui, Huikai Li, Wei Zhang, Qiang Li (2020)Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma
BMC Cancer, 20
Hiromi Nakamura, Y. Arai, Y. Totoki, T. Shirota, Asmaa Elzawahry, Mamoru Kato, N. Hama, F. Hosoda, Tomoko Urushidate, Shoko Ohashi, N. Hiraoka, H. Ojima, K. Shimada, T. Okusaka, T. Kosuge, S. Miyagawa, T. Shibata (2015)Genomic spectra of biliary tract cancer
Nature Genetics, 47
A. Boscoe, C. Rolland, R. Kelley (2019)Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review.
Journal of gastrointestinal oncology, 10 4
T. Boerner, E. Drill, L. Pak, Bastien Nguyen, C. Sigel, A. Doussot, P. Shin, D. Goldman, M. Gonen, P. Allen, V. Balachandran, A. Cercek, J. Harding, D. Solit, N. Schultz, Ritika Kundra, H. Walch, M. D'Angelica, R. DeMatteo, J. Drebin, N. Kemeny, T. Kingham, Amber Simpson, J. Hechtman, E. Vakiani, M. Lowery, J. Ijzermans, S. Buettner, B. Koerkamp, M. Doukas, R. Chandwani, W. Jarnagin (2021)Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma
GK Abou-Alfa, T Macarulla, MM Javle, RK Kelley, SJ Lubner, J Adeva (2020)Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Lancet Oncol, 21
D. Sia, A. Villanueva, S. Friedman, J. Llovet (2017)Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.
Gastroenterology, 152 4
Pu Wang, Q. Dong, Chong Zhang, Pei-Fen Kuan, Yufeng Liu, W. Jeck, J. Andersen, Wenqing Jiang, G. Savich, Ting‐Xu Tan, J. Auman, J. Hoskins, Anne Misher, C. Moser, Scott Yourstone, J. Kim, K. Cibulskis, G. Getz, H. Hunt, S. Thorgeirsson, L. Roberts, D. Ye, K. Guan, Y. Xiong, L. Qin, Derek Chiang (2012)Mutations in Isocitrate Dehydrogenase 1 and 2 Occur Frequently in Intrahepatic Cholangiocarcinomas and Share Hypermethylation Targets with Glioblastomas
MA Lowery, R Ptashkin, E Jordan, MF Berger, A Zehir, M Capanu (2018)Comprehensive molecular profiling of intra-hepatic and extrahepatic cholangiocarcinomas: potential targets for intervention
Clin Cancer Res, 24
M. Simbolo, M. Fassan, A. Ruzzenente, A. Mafficini, L. Wood, V. Corbo, D. Melisi, G. Malleo, C. Vicentini, G. Malpeli, D. Antonello, Nicola Sperandio, P. Capelli, A. Tomezzoli, C. Iacono, R. Lawlor, C. Bassi, R. Hruban, A. Guglielmi, G. Tortora, F. Braud, A. Scarpa (2014)Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups
M. Niger, F. Nichetti, A. Casadei‐Gardini, M. Rizzato, C. Pircher, M. Bini, A. Franza, M. Rimini, V. Burgio, C. Sposetti, L. Fornaro, I. Rapposelli, Francesco D'Amico, G. Aprile, C. Vivaldi, G. Frassineti, M. Milione, G. Leoncini, A. Cappetta, E. Vasile, M. Fassan, F. Morano, F. Perrone, E. Tamborini, G. Pruneri, S. Lonardi, V. Mazzaferro, F. Pietrantonio, M. Bartolomeo, F. Braud (2022)Platinum sensitivity in patients with IDH1/2 mutated vs wild‐type intrahepatic cholangiocarcinoma: A propensity score‐based study
International Journal of Cancer, 151
M. Rimini, E. Loi, C. Fabregat-Franco, V. Burgio, S. Lonardi, M. Niger, M. Scartozzi, Ilario Raposelli, G. Aprile, F. Ratti, F. Pedica, H. Verdaguer, M. Rizzato, F. Nichetti, E. Lai, A. Cappetta, T. Macarulla, M. Fassan, F. Braud, A. Pretta, Francesca Simionato, F. Cobelli, L. Aldrighetti, L. Fornaro, S. Cascinu, Zavattari Patrizia, A. Casadei‐Gardini (2022)Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters.
European journal of cancer, 175
M. Rimini, T. Macarulla, V. Burgio, S. Lonardi, M. Niger, M. Scartozzi, I. Rapposelli, G. Aprile, F. Ratti, F. Pedica, H. Verdaguer, F. Nappo, F. Nichetti, E. Lai, M. Valgiusti, A. Cappetta, Carles Febregat, M. Fassan, F. Braud, M. Puzzoni, G. Frassineti, Francesca Simionato, F. Cobelli, L. Aldrighetti, L. Fornaro, S. Cascinu, A. Casadei‐Gardini (2022)Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma.
European journal of cancer, 171
M. Rimini, V. Burgio, L. Antonuzzo, L. Rimassa, E. Oneda, D. Lavacchi, N. Personeni, F. Ratti, F. Pedica, A. Corte, M. Persano, F. Cobelli, L. Aldrighetti, M. Scartozzi, S. Cascinu, A. Casadei‐Gardini (2022)Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis
Targeted Oncology, 17
M. Rimini, M. Puzzoni, F. Pedica, N. Silvestris, L. Fornaro, G. Aprile, E. Loi, O. Brunetti, C. Vivaldi, Francesca Simionato, P. Zavattari, M. Scartozzi, V. Burgio, F. Ratti, L. Aldrighetti, S. Cascinu, A. Casadei‐Gardini (2021)Cholangiocarcinoma: new perspectives for new horizons
Expert Review of Gastroenterology & Hepatology, 15
L. Goyal, A. Govindan, Rahul Sheth, V. Nardi, L. Blaszkowsky, J. Faris, J. Clark, D. Ryan, E. Kwak, Jill Allen, Janet Murphy, Supriya Saha, Theodore Hong, J. Wo, C. Ferrone, Kenneth Tanabe, Dawn Chong, V. Deshpande, D. Borger, A. Iafrate, N. Bardeesy, Hui Zheng, Andrew Zhu (2015)Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
The oncologist, 20 9
Y. Jiao, T. Pawlik, R. Anders, F. Selaru, M. Streppel, Donald Lucas, N. Niknafs, V. Guthrie, A. Maitra, P. Argani, G. Offerhaus, J. Roa, L. Roberts, G. Gores, I. Popescu, S. Alexandrescu, S. Dima, M. Fassan, M. Simbolo, A. Mafficini, P. Capelli, R. Lawlor, A. Ruzzenente, A. Guglielmi, G. Tortora, F. Braud, A. Scarpa, W. Jarnagin, D. Klimstra, R. Karchin, V. Velculescu, R. Hruban, B. Vogelstein, K. Kinzler, N. Papadopoulos, L. Wood (2013)Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
Nature Genetics, 45
G Wintheiser, T Zemla, Q Shi, N Tran, K Prasai, SH Tella (2022)Isocitrate dehydrogenase-mutated cholangiocarcinoma: natural history and clinical outcomes
JCO Precis Oncol, 6
BackgroundIsocitrate dehydrogenase-1 (IDH1) mutations occur in a significant proportion of intrahepatic cholangiocarcinomas (iCCAs). No data are available regarding the prognostic impact of IDH1 mutations in advanced iCCA patients after progression on first-line therapies.ObjectiveWe investigated the role of IDH1 mutation in advanced iCCA after progression on first-line therapies.Patients and MethodsAfter progression on first-line therapies for advanced iCCA, consecutive patients were retrospectively collected. The IDH1 status was tested at baseline. This analysis aimed to examine the association between the presence of IDH1 missense mutations and survival outcomes in patients with advanced iCCA treated with a second-line therapy.ResultsThe analysis included 119 patients; 56/119 (47%) were IDH1 mutated (IDH1m) and 63/119 (53%) were IDH1 wild type (IDH1 WT). At univariate analysis for overall survival (OS), the presence of IDH1 mutation was associated with a worse median OS (mOS; 8.2 vs. 14.1 months; hazard ratio [HR] 1.9, 95% confidence interval [CI] 1.2–3.0, p = 0.0047). Patients harboring IDH1 mutations showed a worse objective response rate (ORR) compared with patients without IDH1 mutation, whereas no significant differences in disease control rate (DCR) were found. Multivariate analysis confirmed IDH1 mutations as an independent negative prognostic factor for OS (HR 1.7, 95% CI 1.1–2.7, p = 0.0256). By evaluating only patients receiving FOLFOX as second-line therapy, no statistically significant differences were found in terms of both OS and PFS between IDH1m and IDH1 WT patients. In this subset of patients, those harboring an IDH1 mutation showed a worse ORR and DCR compared with those without. Finally, at univariate analysis for OS from third-line treatment, the presence of an IDH1 mutation was associated with a trend toward a worse mOS (6.0 vs. 11.9 months; HR 1.6, 95% CI 0.8–3.2, p = 0.25).ConclusionThe present analysis constitutes the first evidence of a negative prognostic impact of IDH1 mutations in a cohort of patients treated after progression on first-line therapies in contrast to IDH1 inhibitors.
Targeted Oncology – Springer Journals
Published: Jan 1, 2023
Access the full text.
Sign up today, get DeepDyve free for 14 days.